These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1011 related items for PubMed ID: 15126522

  • 1. Induction of multiple follicular development by a single dose of long-acting recombinant follicle-Stimulating hormone (FSH-CTP, corifollitropin alfa) for controlled ovarian stimulation before in vitro fertilization.
    Devroey P, Fauser BC, Platteau P, Beckers NG, Dhont M, Mannaerts BM.
    J Clin Endocrinol Metab; 2004 May; 89(5):2062-70. PubMed ID: 15126522
    [Abstract] [Full Text] [Related]

  • 2. Pharmacokinetics and follicular dynamics of corifollitropin alfa versus recombinant FSH during ovarian stimulation for IVF.
    Fauser BC, Alper MM, Ledger W, Schoolcraft WB, Zandvliet A, Mannaerts BM, Engage Investigators.
    Reprod Biomed Online; 2010 Nov; 21(5):593-601. PubMed ID: 20843746
    [Abstract] [Full Text] [Related]

  • 3. Corifollitropin alfa compared with follitropin beta in poor responders undergoing ICSI: a randomized controlled trial.
    Kolibianakis EM, Venetis CA, Bosdou JK, Zepiridis L, Chatzimeletiou K, Makedos A, Masouridou S, Triantafillidis S, Mitsoli A, Tarlatzis BC.
    Hum Reprod; 2015 Feb; 30(2):432-40. PubMed ID: 25492411
    [Abstract] [Full Text] [Related]

  • 4. Pharmacodynamics of a single low dose of long-acting recombinant follicle-stimulating hormone (FSH-carboxy terminal peptide, corifollitropin alfa) in women with World Health Organization group II anovulatory infertility.
    Balen AH, Mulders AG, Fauser BC, Schoot BC, Renier MA, Devroey P, Struijs MJ, Mannaerts BM.
    J Clin Endocrinol Metab; 2004 Dec; 89(12):6297-304. PubMed ID: 15579793
    [Abstract] [Full Text] [Related]

  • 5. A randomized comparison of two ovarian stimulation protocols with gonadotropin-releasing hormone (GnRH) antagonist cotreatment for in vitro fertilization commencing recombinant follicle-stimulating hormone on cycle day 2 or 5 with the standard long GnRH agonist protocol.
    Hohmann FP, Macklon NS, Fauser BC.
    J Clin Endocrinol Metab; 2003 Jan; 88(1):166-73. PubMed ID: 12519847
    [Abstract] [Full Text] [Related]

  • 6. Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant follicle-stimulating hormone and GnRH antagonist cotreatment.
    Beckers NG, Macklon NS, Eijkemans MJ, Ludwig M, Felberbaum RE, Diedrich K, Bustion S, Loumaye E, Fauser BC.
    J Clin Endocrinol Metab; 2003 Sep; 88(9):4186-92. PubMed ID: 12970285
    [Abstract] [Full Text] [Related]

  • 7. High ovarian response does not jeopardize ongoing pregnancy rates and increases cumulative pregnancy rates in a GnRH-antagonist protocol.
    Fatemi HM, Doody K, Griesinger G, Witjes H, Mannaerts B.
    Hum Reprod; 2013 Feb; 28(2):442-52. PubMed ID: 23136144
    [Abstract] [Full Text] [Related]

  • 8. Large, comparative, randomized double-blind trial confirming noninferiority of pregnancy rates for corifollitropin alfa compared with recombinant follicle-stimulating hormone in a gonadotropin-releasing hormone antagonist controlled ovarian stimulation protocol in older patients undergoing in vitro fertilization.
    Boostanfar R, Shapiro B, Levy M, Rosenwaks Z, Witjes H, Stegmann BJ, Elbers J, Gordon K, Mannaerts B, Pursue investigators.
    Fertil Steril; 2015 Jul; 104(1):94-103.e1. PubMed ID: 26003273
    [Abstract] [Full Text] [Related]

  • 9. [Effect of domestic highly purified urinary follicle stimulating hormone on outcomes of in vitro fertilization-embryo transfer in controlled ovarian stimulation].
    Ye H, Huang GN, Cao YX, Zhong Y, Huang YH, Zhu GJ, Zhou LM, Chen ZJ, Shi JZ, Zeng Y, Weng N, Huang XF, Yang J, Zhu YM, Li YP, Yi D, Zhuang GL.
    Zhonghua Fu Chan Ke Za Zhi; 2013 Nov; 48(11):838-42. PubMed ID: 24444561
    [Abstract] [Full Text] [Related]

  • 10. Corifollitropin alfa followed by highly purified HMG versus recombinant FSH in young poor ovarian responders: a multicentre randomized controlled clinical trial.
    Drakopoulos P, Vuong TNL, Ho NAV, Vaiarelli A, Ho MT, Blockeel C, Camus M, Lam AT, van de Vijver A, Humaidan P, Tournaye H, Polyzos NP.
    Hum Reprod; 2017 Nov 01; 32(11):2225-2233. PubMed ID: 29040589
    [Abstract] [Full Text] [Related]

  • 11. A randomized dose-response trial of a single injection of corifollitropin alfa to sustain multifollicular growth during controlled ovarian stimulation.
    Corifollitropin Alfa Dose-finding Study Group.
    Hum Reprod; 2008 Nov 01; 23(11):2484-92. PubMed ID: 18684735
    [Abstract] [Full Text] [Related]

  • 12. Corifollitropin alfa: a review of its use in controlled ovarian stimulation for assisted reproduction.
    Croxtall JD, McKeage K.
    BioDrugs; 2011 Aug 01; 25(4):243-54. PubMed ID: 21815699
    [Abstract] [Full Text] [Related]

  • 13. Administration of corifollitropin alfa on Day 2 versus Day 4 of the cycle in a GnRH antagonist protocol: a randomized controlled pilot study.
    Blockeel C, Polyzos NP, Derksen L, De Brucker M, Vloeberghs V, van de Vijver A, De Vos M, Tournaye H.
    Hum Reprod; 2014 Jul 01; 29(7):1500-7. PubMed ID: 24813196
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Recombinant follicle-stimulating hormone and recombinant luteinizing hormone versus recombinant follicle-stimulating hormone alone during GnRH antagonist ovarian stimulation in patients aged ≥35 years: a randomized controlled trial.
    Vuong TN, Phung HT, Ho MT.
    Hum Reprod; 2015 May 01; 30(5):1188-95. PubMed ID: 25740882
    [Abstract] [Full Text] [Related]

  • 16. Initiation of ovarian stimulation independent of the menstrual cycle: a case-control study.
    Buendgen NK, Schultze-Mosgau A, Cordes T, Diedrich K, Griesinger G.
    Arch Gynecol Obstet; 2013 Oct 01; 288(4):901-4. PubMed ID: 23545834
    [Abstract] [Full Text] [Related]

  • 17. A randomized controlled trial of increasing recombinant follicle-stimulating hormone after initiating a gonadotropin-releasing hormone antagonist for in vitro fertilization-embryo transfer.
    Propst AM, Bates GW, Robinson RD, Arthur NJ, Martin JE, Neal GS.
    Fertil Steril; 2006 Jul 01; 86(1):58-63. PubMed ID: 16753156
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Recombinant luteinizing hormone supplementation to recombinant follicle-stimulating hormone induced ovarian hyperstimulation in the GnRH-antagonist multiple-dose protocol.
    Griesinger G, Schultze-Mosgau A, Dafopoulos K, Schroeder A, Schroer A, von Otte S, Hornung D, Diedrich K, Felberbaum R.
    Hum Reprod; 2005 May 01; 20(5):1200-6. PubMed ID: 15665010
    [Abstract] [Full Text] [Related]

  • 20. Oestradiol and immunoreactive inhibin-like secretory patterns following controlled ovarian hyperstimulation with urinary (Metrodin) or recombinant follicle stimulating hormone (Puregon).
    Mitchell R, Buckler HM, Matson P, Lieberman B, Burger HG, Hilton B, Horne G, Dyson M, Robertson WR.
    Hum Reprod; 1996 May 01; 11(5):962-7. PubMed ID: 8671371
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 51.